# Submission rejected

## DRAFT REJECTED

**SPAR verdict:** `reject_critical` (3-0 unanimous reject).

## Proposed thesis (rejected)

> the loss of SIRT2 blunted the response of AMPK to metformin treatment in mice infused with Ang II and repressed the metformin-mediated reduction of cardiac hypertrophy and protection of cardiac function.

## Panel reviews

### `evidence_auditor` — `reject` (score 1)

The submission contains a critical failure in the citation trace for claim C021. The alias match for 'Loss' was resolved to 'AZASETRON', which is a completely unrelated pharmacological agent (a 5-HT3 receptor antagonist) and bears no relation to the loss of the SIRT2 protein discussed in the thesis and claims. This represents a fundamental failure in the trace process, rendering the evidence for C021 invalid.

**Flagged claims:** C021

### `domain_skeptic` — `reject` (score 3)

The submission suffers from severe mechanism inflation and a critical failure in entity resolution. The claims extrapolate findings from a highly specific murine model (Ang II-infused Sirt2 knockout mice) to a general conclusion about metformin's cardioprotective effects. More alarmingly, the citation trace for C021 reveals a catastrophic alias match where 'Loss' (referring to the loss of a protein/gene) was resolved to 'AZASETRON', a completely unrelated pharmaceutical agent. This indicates a fundamental breakdown in the evidence chain.

Furthermore, the claims frame the SIRT2-AMPK axis as a definitive requirement for metformin's action in the heart, yet the evidence is limited to a single preclinical study in mice. There is no calibration to account for the fact that these results in a knockout model under Ang II stress do not necessarily translate to the broader clinical application of metformin in human cardiac hypertrophy.

**Flagged claims:** C020, C021

### `final_judge` — `reject` (score 1)

I align with both the Evidence Auditor and the Domain Skeptic. The submission contains a catastrophic failure in the citation trace for C021, where the term 'Loss' (referring to the genetic knockout of SIRT2) was erroneously resolved as 'AZASETRON'. This is not a minor clerical error but a fundamental breakdown in entity resolution that invalidates the evidence chain for the claim. 

Additionally, I concur with the Domain Skeptic regarding the over-extrapolation of the findings. The thesis presents a specific mechanistic interaction in a murine model under Ang II infusion as a general rule, without sufficient calibration for the limitations of preclinical knockout models. Given the combination of a hallucinated alias match and mechanism inflation, the submission fails to meet the basic standards of research integrity.

**Flagged claims:** C020, C021
